Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer

Journal of Clinical Oncology

Volumn 27, Issue 22, 2009, Pages 3577-3583

  Chan, June M ^a   Oh, William K ^a   Xie, Wanling ^a   Regan, Meredith M ^a   Stampfer, Meir J ^a   King, Irena B ^a   Abe, Miyako ^a   Kantoff, Philip W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MANGANESE SUPEROXIDE DISMUTASE; PROSTATE SPECIFIC ANTIGEN; SELENIUM; SUPEROXIDE DISMUTASE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; GENE; GENOTYPE; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK REDUCTION; SOD2 GENE; BLOOD; CANCER INVASION; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CROSS-SECTIONAL STUDY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; PREDICTION AND FORECASTING; PROBABILITY; PROSTATE TUMOR; RISK ASSESSMENT; STATISTICAL MODEL; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; COHORT STUDIES; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SELENIUM; SUPEROXIDE DISMUTASE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 68949086797     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.8938     Document Type: Article

References (52)

1. Peters U, Foster CB, Chatterjee N, et al: Serum selenium and risk of prostate cancer: A nested case-control study. Am J Clin Nutr 85:209-217, 2007
2. Brinkman M, Reulen RC, Kellen E, et al: Are men with low selenium levels at increased risk of prostate cancer? Eur J Cancer 42:2463-2471, 2006
3. Etminan M, FitzGerald JM, Gleave M, et al: Intake of selenium in the prevention of prostate cancer: A systematic review and meta-analysis. Cancer Causes Control 16:1125-1131, 2005
4. Allen NE, Morris JS, Ngwenyama RA, et al: A case-control study of selenium in nails and prostate cancer risk in British men. Br J Cancer 90:1392-1396, 2004
5. Brooks JD, Metter EJ, Chan DW, et al: Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 166:2034-2038, 2001
6. Clark LC, Combs GF Jr, Turnbull BW, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial - Nutritional Prevention of Cancer Study Group. JAMA 276:1957-1963, 1996
7. Vogt TM, Ziegler RG, Graubard BI, et al: Serum selenium and risk of prostate cancer in U.S. blacks and whites. Int J Cancer 103:664-670, 2003
8. Nomura AM, Lee J, Stemmermann GN, et al: Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 9:883-887, 2000
9. Yoshizawa K, Willett WC, Morris SJ, et al: Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 90:1219-1224, 1998
10. van den Brandt PA, Zeegers MP, Bode P, et al: Toenail selenium levels and the subsequent risk of prostate cancer: A prospective cohort study. Cancer Epidemiol Biomarkers Prev 12:866-871, 2003
11. Combs GF Jr: Status of selenium in prostate cancer prevention. Br J Cancer 91:195-199, 2004
12. Nelson MA, Porterfield BW, Jacobs ET, et al: Selenium and prostate cancer prevention. Semin Urol Oncol 17:91-96, 1999
13. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al: Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: An analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 91: 608-612, 2003
14. Li H, Stampfer MJ, Giovannucci EL, et al: A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 96:696-703, 2004
15. Combs GF, Clark LC, Turnbull BW: Reduction of cancer risk with an oral supplement of selenium. Biomed Environ Sci 10:227-234, 1997
16. Combs GF Jr, Clark LC, Turnbull BW: Reduction of cancer mortality and incidence by selenium supplementation. Med Klin 92:42-45, 1997 (suppl 3)
17. Helzlsouer KJ, Huang HY, Alberg AJ, et al: Association between alpha-tocopherol, gammatocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 92:2018-2023, 2000
18. Corcoran NM, Najdovska M, Costello AJ: Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol 171: 907-910, 2004
19. Waters DJ, Shen S, Cooley DM, et al: Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Natl Cancer Inst 95:237-241, 2003
20. Webber MM, Perez-Ripoll EA, James GT: Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro. Biochem Biophys Res Commun 130:603-609, 1985
21. Venkateswaran V, Fleshner NE, Sugar LM, et al: Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 64:5891-5896, 2004
22. Karunasinghe N, Ryan J, Tuckey J, et al: DNA stability and serum selenium levels in a high-risk group for prostate cancer. Cancer Epidemiol Biomarkers Prev 13:391-397, 2004
23. Duffield-Lillico AJ, Reid ME, Turnbull BW, et al: Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: A summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11:630-639, 2002
24. Klein EA, Thompson IM, Lippman SM, et al: SELECT: The next prostate cancer prevention trial - Selenium and Vitamin E Cancer Prevention Trial. J Urol 166:1311-1315, 2001
25. Lippman SM, Klein EA, Goodman PJ, et al: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301:39-51, 2008
26. Li H, Kantoff PW, Giovannucci E, et al: Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 65:2498-2504, 2005
27. Sutton A, Khoury H, Prip-Buus C, et al: The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 13:145-157, 2003
28. Oh WK, Hayes J, Evan C, et al: Development of an integrated prostate cancer research information system. Clin Genitourin Cancer 5:61-66, 2006
29. Rosenblum JS, Gilula NB, Lerner RA: On signal sequence polymorphisms and diseases of distribution. Proc Natl Acad Sci U S A 93:4471-4473, 1996
30. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, et al: Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene: A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochem Biophys Res Commun 226:561-565, 1996
31. Satia JA, King IB, Morris JS, et al: Toenail and plasma levels as biomarkers of selenium exposure. Ann Epidemiol 16:53-58, 2006
32. Ericson SP, McHalsky ML, Rabinow BE, et al: Sampling and analysis techniques for monitoring serum for trace elements. Clin Chem 32:1350-1356, 1986
33. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
34. Deddens JA, Petersen MR: Approaches for estimating prevalence ratios. Occup Environ Med 65:481:501-506, 2008
35. Lawson KA, Wright ME, Subar A, et al: Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 99:754-764, 2007
36. Waters DJ, Shen S, Glickman LT, et al: Prostate cancer risk and DNA damage: Translational significance of selenium supplementation in a canine model. Carcinogenesis 26:1256-1262, 2005
37. Choi JY, Neuhouser ML, Barnett M, et al: Iron intake, oxidative stress-related genes (MnSOD and MPO), and prostate cancer risk in CARET cohort. Carcinogenesis 29:964-970, 2008
38. Kang D, Lee KM, Park SK, et al: Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev 16:1581-1586, 2007
39. Woodson K, Tangrea JA, Lehman TA, et al: Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes Control 14:513-518, 2003
40. Choi JY, Neuhouser ML, Barnett M, et al: Polymorphisms in oxidative stress-related genes are not associated with prostate cancer risk in heavy smokers. Cancer Epidemiol Biomarkers Prev 16: 1115-1120, 2007
41. Taufer M, Peres A, de Andrade VM, et al: Is the Val16Ala manganese superoxide dismutase polymorphism associated with the aging process? J Gerontol A Biol Sci Med Sci 60:432-438, 2005
42. Ergen HA, Narter F, Timirci O, et al: Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: A case-control study. Anticancer Res 27:1227-1230, 2007
43. Slanger TE, Chang-Claude J, Wang-Gohrke S: Manganese superoxide dismutase Ala-9Val polymorphism, environmental modifiers, and risk of breast cancer in a German population. Cancer Causes Control 17:1025-1031, 2006
44. Silva SN, Cabral MN, Bezerra de Castro G, et al: Breast cancer risk and polymorphisms in genes involved in metabolism of estrogens (CYP17, HSD17beta1, COMT and MnSOD): Possible protective role of MnSOD gene polymorphism Val/Ala and Ala/Ala in women that never breast fed. Oncol Rep 16:781-788, 2006
45. Cai Q, Shu XO, Wen W, et al: Genetic polymorphism in the manganese superoxide dismutase gene, antioxidant intake, and breast cancer risk: Results from the Shanghai Breast Cancer Study. Breast Cancer Res 6:R647-R655, 2004
46. Ambrosone CB, Freudenheim JL, Thompson PA, et al: Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res 59:602-606, 1999
47. Tamimi RM, Hankinson SE, Spiegelman D, et al: Manganese superoxide dismutase polymorphism, plasma antioxidants, cigarette smoking, and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 13:989-996, 2004
48. Millikan RC, Player J, de Cotret AR, et al: Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case-control study of African Americans and whites. Breast Cancer Res 6:R264-R274, 2004
49. Hung RJ, Boffetta P, Brennan P, et al: Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis 25:973-978, 2004
50. Han J, Colditz GA, Hunter DJ: Manganese superoxide dismutase polymorphism and risk of skin cancer (United States). Cancer Causes Control 18:79-89, 2007
51. Husbeck B, Nonn L, Peehl DM, et al: Tumorselective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate 66:218-225, 2006
52. Zhong W, Yan T, Webber MM, et al: Alteration of cellular phenotype and responses to oxidative stress by manganese superoxide dismutase and a superoxide dismutase mimic in RWPE-2 human prostate adenocarcinoma cells. Antioxid Redox Signal 6:513-522, 2004